CTNNB1 and Miyoshi myopathy: However, the OS of patients with MM and APC/CTNNB1 genetic aberrations who received immunotherapies was not significantly different from that of patients without (median OS 26.1 months vs. 29.9 months, respectively, log-rank p = 0.33).